Makary Mina S, Khandpur Umang, Cloyd Jordan M, Mumtaz Khalid, Dowell Joshua D
Division of Vascular and Interventional Radiology, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Cancers (Basel). 2020 Jul 15;12(7):1914. doi: 10.3390/cancers12071914.
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and third leading cause of cancer-related mortality worldwide. While surgical resection and transplantation are the standard first-line treatments for early-stage HCC, most patients do not fulfill criteria for surgery. Fortunately, catheter-directed and percutaneous locoregional approaches have evolved as major treatment modalities for unresectable HCC. Improved outcomes have been achieved with novel techniques which can be employed for diverse applications ranging from curative-intent for small localized tumors, to downstaging or bridging to resection and transplantation for early and intermediate disease, and locoregional control and palliation for advanced disease. This review explores recent advances in liver-directed techniques for HCC including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies, with a focus on patient selection, procedural technique, periprocedural management, and outcomes.
肝细胞癌(HCC)是最常见的原发性肝脏恶性肿瘤,也是全球癌症相关死亡的第三大主要原因。虽然手术切除和移植是早期HCC的标准一线治疗方法,但大多数患者不符合手术标准。幸运的是,导管导向和经皮局部区域治疗方法已发展成为不可切除HCC的主要治疗方式。通过新技术已取得了更好的治疗效果,这些新技术可用于多种应用,从针对小的局限性肿瘤的根治性治疗,到对早期和中期疾病进行降期或过渡到切除和移植,以及对晚期疾病进行局部区域控制和姑息治疗。本综述探讨了用于HCC的肝脏导向技术的最新进展,包括单纯经动脉栓塞、化疗栓塞、放射性栓塞和消融治疗,重点关注患者选择、操作技术、围手术期管理和治疗效果。